This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
idh2
IDH2
IDH2 (mitochondrial isocitrate dehydrogenase 2) catalyzes isocitrate → α-KG in the TCA cycle; IDH2 R140Q/R172K gain-of-function mutations produce 2-hydroxyglutarate → TET2/KDM inhibition → DNA hypermethylation; enasidenib is the approved IDH2 inhibitor for IDH2-mutant AML.
Entry Metadata
| Field | Value |
|---|---|
| ID | idh2 |
| Name | IDH2 |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 03-molecular |
Cross-Atlas Connections
Sources
- Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553-567. · PubMed 21130701
- Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722-731. · PubMed 28588020